Back to search

Ireland· IE-PA-PA0865/005/001

Nebilet 5 mg tablets

A nebivolol product containing nebivolol, registered in Ireland by Menarini International Operations Luxembourg S.A.. The same ATC class is registered in 16 of our 19 countries.

ATC C07AB12

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedNebilet 5 mg tabletsATCC07AB12REGISTER NO.IE-PA-PA0865/005/001PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Nebivolol is registered in 16 of 19 countries.

Countries holding a registration under ATC C07AB12 (nebivolol), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Nebivolol · ATC C07AB12

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nebivolol costs, country by country.

Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.092 in United States to $0.39 in Switzerland — a ×4.2 gap.

  • 5 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Nebivolol · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.39
  • ES Spain$0.32
  • IT Italy$0.25
  • FR France$0.14
  • US United States$0.092 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Nebivolol
Manufacturer
Menarini International Operations Luxembourg S.A.
Country
Ireland (IE)
ATC code
C07AB12
ATC class
Nebivolol
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA0865/005/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

273 interactions on record for nebivolol.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nebivolol · interactions on record

273 records

  • 10 severe
  • 202 moderate
  • 17 minor

Most severe, free to view

  • DolasetronA04AA04severe
  • TheophyllinC01EB28severe
  • CeritinibL01ED02severe
  • CeritinibL01XE28severe

44 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nebivolol in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nebivolol products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Nebilan, Nebivolol +pharma
  • Belgium · Nebivolol Ab, Nebivolol Eg
  • Bulgaria · Nebilan, Nebivolol Sandoz
  • Cyprus · Lobivon, Nebivolol Accord
  • Czechia · Nebilet, Nebivolol Medreg
  • Germany · Nebilet, Nebivolol 089pharm
  • Denmark · Hypoloc, Nebivolol Accord
  • Estonia · Nebicard, Nebilet
  • Spain · Insucor, Lobivon
  • Finland · Hypoloc, Nebivolol Accord
  • France · Nebilox, Nebivolol Almus
  • United Kingdom (Northern Ireland) · Nebilet, Nebivolol
  • Greece · Bivol, Hypoloc
  • Croatia · Massido, Nebilet
  • Hungary · Nebibeta, Nebilet
  • Italy · Lobivon, Nebilox
  • Lithuania · Nebicard, Nebilet
  • Luxembourg · Nebivolol Eg, Nobiten
  • Latvia · Nebilet, Nebivolol Actavis
  • Malta · Nebilet, Nebivolol Atb
  • Netherlands · Hypoloc, Lobivon
  • Poland · Daneb, Ebivol
  • Portugal · Nebilet, Nebivolol Aurovitas
  • Romania · Nebilet, Nebivolol Gemax Pharma
  • Slovenia · Nebilet, Nebivolol Krka
  • Slovakia · Nebilet, Nebitrix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d8b14239-bbf0-4d65-9bfd-0ed462a93962
GET /v1/drugs/d8b14239-bbf0-4d65-9bfd-0ed462a93962?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "C07AB",
    "C07AB12"
  ],
  "strength": null,
  "pa_number": "PA0865/005/001",
  "substances": [
    "Nebivolol"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "20/05/1996",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": "IC0082-001-002"
}

See everything about nebivolol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.